Notwithstanding the experimental evidence reviewed above regarding murine model CPD-driven TP53 mutagenesis in cutaneous tumors, the current study design only allows for speculative observations regarding the pathogenic significance of pre-mutagenic CPDs in RCC carcinogenesis. This evidence concerns the gene TP53 and renal cell carcinoma.